Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. - Test2 - elhamkhani - TriplyDB

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

http://www.wikidata.org/entity/Q39711077

about

Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer DNA repair targeted therapy: The past or future of cancer treatment?Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy Robustness of DNA repair through collective rate control.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.Cellular responses to Cisplatin-induced DNA damage.XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif Novel role of base excision repair in mediating cisplatin cytotoxicity.Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform Chromium(VI) causes interstrand DNA cross-linking in vitro but shows no hypersensitivity in cross-link repair-deficient human cells Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.DNA repair mechanisms in cancer development and therapy DNA repair: from genome maintenance to biomarker and therapeutic target.The ERCC1 and ERCC4 (XPF) genes and gene products Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.Utilisation of nanoparticle technology in cancer chemoresistance.Novel oxidatively activated agents modify DNA and are enhanced by ercc1 silencing.Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Molecular mechanisms of cisplatin resistance in bladder cancer.H2AX a promising biomarker for lung cancer: a review.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.Unique features of trabectedin mechanism of action.Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Identification of DNA repair gene Ercc1 as a novel target in melanoma.Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.

P2860

Q21195898-999717E8-4934-41BA-A1D3-54E7B5266760 Q26768679-39B4DA51-E70E-4DD8-8FFF-E9811C7658C9 Q27009492-63C022FF-0879-44DF-B5B0-6372043D68D3 Q27022940-36245222-5637-4CC7-A658-E1677ABA9343 Q31151033-9E4EC7C1-87A5-4414-9C6B-7C242E37871F Q33648465-C659009E-BFF2-441F-90EE-254F71C6F13C Q33808509-705D309D-4576-4AEE-9793-5B6E4A190A74 Q34089685-689C4FEA-0F4E-420E-89F2-FFEF53C0AE95 Q34521935-146E4737-E2D7-4EBD-9297-8D2AD2D7A41E Q34722650-818041A4-9430-484E-BF06-8E9143A3A978 Q34762678-475E0E7C-50EA-4DC4-9B24-87E96074FB1C Q34800428-70A82C1D-05E6-422A-ACB8-146DA9A4146E Q34842777-2A7038B9-0A9B-45A7-8A70-138CCD474FED Q34987379-879CA5A2-507F-400B-BD20-816398BC78AE Q34995478-6679DD3E-E7B0-480C-B2C2-DDE5721DED10 Q35223337-853DEA4E-71A2-4A00-B9F3-1F19E77C113A Q35531287-A0F9EC14-0B32-4714-838F-49008EA058FF Q35555880-B1941E75-E63F-4EC5-BC5D-ABF1C7470F88 Q35663361-5A280F97-804F-44E1-BF25-14D7ABC57A41 Q36129322-F7DD79AA-5D7B-4AD7-B35C-64E3DB2C279C Q36296744-F437EEFD-3D7C-4147-A2F6-079F59B5EF9C Q36370912-1A5A9151-4452-43B9-A766-CF8D0DA8D640 Q36421258-AC5CEE43-51D3-4D10-8036-33F44AB38DA7 Q36441829-E8C5D60D-4E4B-4722-B6B3-774B33C495F9 Q36742188-B0877AA3-B09D-4BC3-84C3-FDA1A762E485 Q36910455-B4DC35F7-7C5F-49E4-BD60-3D6FE2D0EF00 Q37122036-EEE29C94-C16B-4196-9D8A-889419B031A0 Q37688903-5F318C2F-64C8-4453-AFA9-285B9CA6566F Q37799220-AEAEE41A-8B19-482B-81F8-B5BE778E8F1C Q37982453-199E3892-4BFE-43A8-B6BD-AAF96490C31B Q38155902-63C10C06-13A8-4B58-B87E-342234A6320A Q38546133-9F788DE6-244D-4D34-9578-94FD0C3F1B8C Q38669051-88C587EE-952F-4167-8CC4-D004B409534D Q38704026-DFA64EA2-AEB2-4234-A259-F7AAB22351CA Q39012252-88E84A4C-DF34-4E18-8764-CC8356D32FF6 Q39199269-6BE2F27E-CBDC-492C-92B1-77A2C195D2C6 Q39372187-5C52804C-6416-4D38-93DC-2F8788790AAE Q39433258-C000C405-9B95-499E-A113-DEF709844216 Q39514514-3048AB29-2445-4ED4-99D0-2B3A2D928CEE Q41549007-52448D74-398A-44FF-8E9C-A2A78CCD5A55

P2860

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

http://www.wikidata.org/entity/Q39711077

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@en

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@nl

type

label

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@en

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@nl

prefLabel

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@en

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

@nl

P1433

Q39711077-C532BA47-D1AF-4568-8059-314C7EE414F8

P1476

Q39711077-CFB28C6B-1B45-46EF-A279-F3A2CF0A314D

P2093

Q39711077-07648728-95D0-4084-80F1-37ECF4C2BD84

Q39711077-1F54FCA4-6AD8-4AFB-8331-9695968F8F7A

Q39711077-33E09247-165E-4AA7-BEE5-99ED3284DA11

Q39711077-3F069DD4-F4ED-48ED-9074-8635D94220CE

P2860

Q39711077-1269341B-862E-4E83-8C1F-637D9F85A108

Q39711077-1BFB2FEF-2267-42A8-BE4D-B875D0E639EC

Q39711077-1D9BAD97-3169-4A1D-B324-20E41A5A26EA

Q39711077-1F135839-63B8-4D9E-A610-312CAF87480B

Q39711077-1F2EFE09-5495-4050-8794-B8EF38865C2B

Q39711077-207BB0FB-2644-4E04-88A4-04D0E37B4054

Q39711077-24105343-D099-43C5-8CA8-5266D943F003

Q39711077-2501D19C-336E-4A5B-8F16-AE5615B4B51C

Q39711077-33E34097-3EF1-441B-B831-566217869E0F

Q39711077-34B22CAD-D930-48B2-9F62-79E02017DF51

P304

Q39711077-2DB023A0-947E-47E6-8C04-EF6DD2DEB148

P31

Q39711077-6ACB4962-2C7C-40A3-8858-FF8FDB2CC27F

P356

Q39711077-AB2CAB48-0F84-425B-9710-07322B280321

P433

Q39711077-17B79AEC-BE74-4CB4-AB7F-747CCD8E4423

P478

Q39711077-3A373563-BD7C-43A1-9A80-0E7E97124565

P50

Q39711077-E2B6000B-D0CB-4282-842A-13476DB50B95

P577

Q39711077-D8B0AB88-743E-4EB4-A925-C5FEB91FA9E5

P5875

Q39711077-4B57F1E5-DA1E-46F2-BDFC-5D9E7C7A437A

P698

Q39711077-16E800DD-B779-47B1-9183-CC6993D475BC

P932

Q39711077-AB5F27BC-9DEA-4532-978F-041A6D5C33B5

P356

J.DNAREP.2010.03.010

P1433

P1476

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells

@en

P2093

Anbarasi Kothandapani

http://www.w3.org/2001/XMLSchema#string

Kristin Tillison

http://www.w3.org/2001/XMLSchema#string

Steve M Patrick

http://www.w3.org/2001/XMLSchema#string

Vivian Kalman-Maltese

http://www.w3.org/2001/XMLSchema#string

P2860

The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair

ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes

Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex

Nucleotide excision repair- and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links

First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure

ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines

The HhH domain of the human DNA repair protein XPF forms stable homodimers

RAD10, an excision repair gene of Saccharomyces cerevisiae, is involved in the RAD1 pathway of mitotic recombination.

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

P304

745-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DNAREP.2010.03.010

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Sanjeevani Arora

P577

2010-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43342621

http://www.w3.org/2001/XMLSchema#string

P698

20418188

http://www.w3.org/2001/XMLSchema#string

P932

4331052

http://www.w3.org/2001/XMLSchema#string